Galleon Pharmaceuticals, Inc. Announces Publication Of Proof-Of-Concept Clinical Studies For GAL-021, Projected Use For The Emerging Perioperative Sleep Apnea Epidemic

HORSHAM, Pa.--(BUSINESS WIRE)--Galleon Pharmaceuticals announced clinically and statistically significant (p<0.01) results from a double-blind, placebo-controlled clinical proof-of-concept study of its lead investigational compound GAL-021 in normal volunteers. The data were published in the most recent issue of Anesthesiology.

The study sought to assess whether GAL-021 stimulated breathing in humans with respiratory depression induced by a potent opioid under conditions common after surgery. Researchers concluded that GAL-021 met or exceeded the study’s pre-defined goals of maintaining both respiration and pain control under these conditions, and called for further clinical exploration of the drug’s safety and efficacy.

Help employers find you! Check out all the jobs and post your resume.